Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Medical Genetics
Published in: BMC Medical Genetics 1/2018

Open Access 01-12-2018 | Research article

The estrogen receptor 1 gene affects bone mineral density and osteoporosis treatment efficiency in Slovak postmenopausal women

Authors: Vladimira Mondockova, Maria Adamkovicova, Martina Lukacova, Birgit Grosskopf, Ramona Babosova, Drahomir Galbavy, Monika Martiniakova, Radoslav Omelka

Published in: BMC Medical Genetics | Issue 1/2018

Login to get access

Abstract

Background

The study investigated the associations of rs9340799:A > G (XbaI) and rs2234693:T > C (PvuII) polymorphisms in the estrogen receptor 1 gene (ESR1) with femoral neck (BMD-FN) and lumbar spine bone mineral density (BMD-LS), biochemical markers of bone turnover, calcium and phosphate levels, fracture prevalence, and a response to two types of anti-osteoporotic therapy in postmenopausal women from southern Slovakia.

Methods

We analysed 343 postmenopausal Slovak women (62.40 ± 0.46 years). The influence of rs9340799 (AA vs. AG + GG) and rs2234693 (TT vs. TC + CC) genotypes on BMD and biochemical markers was evaluated by covariance analysis adjusted for age and BMI. Binary logistic regression was used to evaluate the genotype effect on fracture prevalence. Pharmacogenetic part of the study included women who received a regular therapy of HT (17ß estradiol with progesterone; 1 mg/day for both; N = 76) or SERMs/raloxifene (60 mg/day; N = 64) during 48 months. The genotype-based BMD change was assessed by variance analysis for repeated measurements.

Results

Women with AA genotype of rs9340799 had higher BMD-FN (+ 0.12 ± 0.57 of T-score) and BMD-LS (+ 0.17 ± 0.08 of T-score) in comparison with AG + GG. The rs2234693 polymorphism did not affect any of the monitored parameters. No effect of any ESR1 polymorphisms was found on fracture prevalence. Both types of anti-osteoporotic therapy had a positive effect on BMD improvement in FN and LS sites. Considering the effect of the ESR1 gene within the HT, the subjects with rs9340799/AA genotype showed worse response than those with GG genotype (− 0.26 ± 0.10 of BMD-FN T-score; − 0.35 ± 0.10 of BMD-LS T-score) and also with AG genotype (− 0.22 ± 0.08 of BMD-LS T-score). The rs2234693/TT genotype responded poorer in BMD-LS in comparison with TC (− 0.22 ± 0.08 of T-score) and CC (− 0.35 ± 0.09 of T-score). The effect of the ESR1 gene on raloxifene therapy was reported only in BMD-LS. Subjects with rs9340799/AA genotype had a − 0.30 ± 0.11 of T-score worse response compared to AG genotype. The rs2234693/TT genotype showed − 0.39 ± 0.11 and − 0.46 ± 0.15 lower T-scores in comparison with TC and CC genotypes, respectively.

Conclusions

The rs9340799 polymorphism may contribute to decreased BMD in postmenopausal women from southern Slovakia; however, this is not related to higher fracture prevalence. Concurrently, both polymorphisms affected a response to analysed anti-osteoporotic therapies.
Appendix
Available only for authorised users
Literature
1.
Ralston SH, Uitterlinden AG. Genetics of osteoporosis. Endocr Rev. 2010;31(5):629–62.CrossRef
2.
Ralston SH. Genetic determinants of susceptibility to osteoporosis. Curr Opin Pharmacol. 2003;3(3):286–90.CrossRef
3.
Duncan EL, Danoy P, Kemp JP, Leo PJ, McCloskey E, Nicholson GC, Eastell R, Prince RL, Eisman JA, Jones G, Sambrook PN, Reid IR, Dennison EM, Wark J, Richards JB, Uitterlinden AG, Spector TD, Esapa C, Cox RD, Brown SD, Thakker RV, Addison KA, Bradbury LA, Center JR, Cooper C, Cremin C, Estrada K, Felsenberg D, Glüer CC, Hadler J, Henry MJ, Hofman A, Kotowicz MA, Makovey J, Nguyen SC, Nguyen TV, Pasco JA, Pryce K, Reid DM, Rivadeneira F, Roux C, Stefansson K, Styrkarsdottir U, Thorleifsson G, Tichawangana R, Evans DM, Brown MA. Genome-wide association study using extreme truncate selection identifies novel genes affecting bone mineral density and fracture risk. PLoS Genet. 2011;7(4):e1001372. https://​doi.​org/​10.​1371/​journal.​pgen.​1001372.CrossRefPubMedPubMedCentral
4.
Wang C, Zhang Z, Zhang H, He JW, Gu JM, Hu WW, Hu YQ, Li M, Liu YJ, Fu WZ, Yue H, Ke YH, Zhang ZL. Susceptibility genes for osteoporotic fracture in postmenopausal Chinese women. J Bone Miner Res. 2012;27(12):2582–91.CrossRef
5.
Eastell R. Pathogenesis in postmenopausal osteoporosis. In: Murray JF & Associate editors: Primer on the metabolic bone diseases and disorders of mineral metabolism. USA: American society for bone and mineral research; 6th. 2006. p. 259–262.
6.
Gennari L, Merlotti D, De Paola V, Calabró A, Becherini L, Martini G, Nuti R. Estrogen receptor gene polymorphisms and the genetics of osteoporosis: a HuGE review. Am J Epidemiol. 2005;161(4):307–20.CrossRef
7.
Gennari L, De Paola V, Merlotti D, Martini G, Nuti R. Steroid hormone receptor gene polymorphisms and osteoporosis: a pharmacogenomic review. Expert Opin Pharmacother. 2007;8(5):537–53.CrossRef
8.
Rooney AM, Van der Meulen MCH. Mouse models to evaluate the role of estrogen receptor α in skeletal maintenance and adaptation. Ann N Y Acad Sci. 2017;1410(1):85–92.CrossRef
9.
Becherini L, Gennari L, Masi L, Mansani R, Massart F, Morreli A, Falchetti AA, Gonelii S, Fiorelli G, Tanini A. Evidence of a linkage disequilibrium between polymorhism in the human estrogene receptor alpha gene and their relationship to bone mass variation in postmenopausal Italian woman. Hum Mol Genet. 2000;9(13):2043–50.CrossRef
10.
Van Maeurs JB, Schui SC, Weel AE. Associations of 5′ estrogen receptor alpha gene polymorphism with bone mineral density, vertebral bone area and fracture risk. Hum Mol Genet. 2003;12(14):1745–54.CrossRef
11.
Kobayashi N, Inoue S, Hosoi T, Ouchi Y, Shiraki M, Orimo H. Association of bone mineral density with polymorphism of the estrogen receptor gene. J Bone Miner Res. 1996;11(3):306–11.CrossRef
12.
Kobayashi N, Fujino T, Shirogane T, Furuta I, Kobamatsu Y, Yaegashi M, Sakuragi N, Fujimoto S. Estrogen receptor alpha polymorphism as a genetic marker for bone loss, vertebral fractures and susceptibility to estrogen. Maturitas. 2002;41(3):193–201.CrossRef
13.
Sowers TD, Jannausch ML, Liang W, Willing M. Estrogen receptor genotypes and their associations with the 10-years changes in bone mineral density and osteocalcin concentrations. J Clin Endocrin Metab. 2004;89(2):733–9.CrossRef
14.
Jeedigunta Y, Reddy PRB, Kolla VK, Munshi A, Anathapur V, Narasimilu G, Akka J. Association of estrogen receptor α gene polymorphisms with BMD and their affect on estradiol levels in pre- and postmenopusal woman in south Indian population from Andhra Pradesh. Clin Chim Acta. 2010;411(7–8):597–600.CrossRef
15.
Kurt O, Yilmaz-Aydogan H, Uyar M, Isbir T, Seyhan MF, Can A. Evaluation of ERα and VDR gene polymorphisms in relation to bone mineral density in Turkish postmenopausal women. Mol Biol Rep. 2012;39(6):6723–30.CrossRef
16.
Chen JS, Sambrook PN. Antiresorptive therapies for osteoporosis: a clinical overview. Nat Rev Endocrinol. 2012;8(2):81–91.CrossRef
17.
Pickar JH, Komm BS. Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: a review of effects on the breast. Post Reprod Health. 2015;21(3):112–21.CrossRef
18.
Marini F, Brandi ML. Pharmacogenetics of osteoporosis. Best Pract Res Clin Endocrinol Metab. 2014;28(6):783–93.CrossRef
19.
Salmen T, Heikkinen AM, Mahonen A, Kroger H, Komulainen M, Saarikoski S, Honkanen R, Maenpaa PH. Early postmenopausal bone loss is associated with Pvu II estrogen receptor gene polymorphism in Finnish woman: effect of hormone replacement therapy. J Bone Miner Res. 2000;15(2):315–21.CrossRef
20.
Rapuri P, Gallagher J, Knezetic J, Haynatzka V. Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen. Maturitas. 2006;53(4):371–9.CrossRef
21.
Ongphiphadhanakul B, Chanprasertyothin S, Payatikul P, Tung SS, Piaseu N, Chailurkit L, Chansirikarn S, Puavilai G, Rajatanavin R. Oestrogen-receptor-alpha gene polymorphism affects response in bone mineral density to oestrogen in post-menopausal women. Clin Endocrinol. 2000;52(5):581–5.CrossRef
22.
Pavone V, Testa G, Giardina SMC, Vescio A, Restivo DA, Sessa G. Pharmacological therapy of osteoporosis: a systematic current review of literature. Front Pharmacol. 2017;8:803.CrossRef
23.
Nguyen TV, Eisman JA. Pharmacogenomics of osteoporosis: opportunities and challenges. J Musculoskelet Neuronal Interact. 2006;6:62–72.PubMed
24.
25.
D’Alonzo KT. The Johnson-Neyman procedure as an alternative to ANCOVA. West J Nurs Res. 2004;26(7):804–12.CrossRef
26.
Albagha OM, McGuigan FE, Reid DM, Ralston SH. Estrogen receptor alpha gene plymorphism and bone mineral density: haplotype analysis in woman from the UnitedKingdom. J Bone Min Res. 2001;16(1):128–34.CrossRef
27.
Bustamante M, Nogués X, Enjuanes A, Elosua R, García-Giralt N, Pérez-Edo L, Cáceres E, Carreras R, Mellibovsky L, Balcells S, Díez-Pérez A, Grinberg D. COL1A1, ESR1, VDR and TGFB1 polymorphisms and haplotypes in relation to BMD in Spanish postmenopausal women. Osteoporos Int. 2007;18(2):235–43.CrossRef
28.
Matsushita H, Kurabayashi T, Tomita M, Tanaka K. Effects of vitamin D and estrogen receptor gene polymorphisms on the changes in lumbar bone mineral density with multiple pregnancies in Japanese women. Hum Reprod. 2004;19(1):59–64.CrossRef
29.
Nam HS, Shin MH, Kweon SS, Park KS, Sohn SJ, Rhee JA, Choi JS, Son MH. Association of estrogen alpha receptor gene polymorphism with bone mineral density in Korean women. J Bone Min Metab. 2005;23(1):84–5.CrossRef
30.
Dai X, Wang C, Dai J, Shi D, Xu Z, Chen D, Teng H, Jiang Q. Association of single nucleotide polymorphisms in estrogen receptor alpha gene with susceptibility to knee osteoarthritis: a case-control study in a Chinese Han population. Biomed Res Int. 2014;2014:151457.PubMedPubMedCentral
31.
Bagger YZ, Jorgensen HL, Heegard AM, Bayer L, Hansen L, Hassager C. No major effect of estrogen receptor gene polymorphisms on bone mineral density of bone loss in postmenopausal Danish women. Bone. 2000;26(2):111–6.CrossRef
32.
Tanriover MD, Tatar GB, Uluturk TD, Erden DD, Tanriover A, Kilicarlslan A, Oz SG, Yurter HE, Sozen T, Guven GS. Evaluation of the effects of vitamin D receptor and estrogen receptor 1 gene polymorphisms on bone mineral density in postmenopausal women. Clin Rheumatol. 2010;29(11):1285–93.CrossRef
33.
Ioannidis JP, Stavrou I, Trikalinos TA, Zois C, Brandi ML, Gennari L, Albagha O, Ralston SH, Tsatsoulis A. ER-alpha genetics meta-analysis. Association of polymorphisms of the estrogen receptor alpha gene with bone mineral density and fracture risk in women: a meta-analysis. J Bone Miner Res. 2002;17(11):2048–60.CrossRef
34.
Zhu H, Jiang J, Wang Q, Zong J, Zhang L, Ma T, Xu Y, Zhang L. Associations between ERα/β gene polymorphisms and osteoporosis susceptibility and bone mineral density in postmenopausal women: a systematic review and meta-analysis. BMC Endocr Disord. 2018;18(1):11.CrossRef
35.
Correa-Rodríguez M, Viatte S, Massey J, Schmidt-RioValle J, Rueda-Medina B, Orozco G. Analysis of SNP-SNP interactions and bone quantitative ultrasound parameter in early adulthood. BMC Med Genet. 2017;18(1):107.CrossRef
36.
37.
Zmuda JM, Cauley JA, Ferrell RE, Nevitt MC, Feingold E, Ensrud K, Stone KL, Hochberg MC, Harris EL, Cummings SR. Familial resemblance in fall-related risk factors in older woman. Calcif Tissue Int. 2000;67:497.
38.
Boyde A. The real response of bone to exercise. J Anat. 2003;203(2):173–89.CrossRef
39.
Estrada K, Styrkarsdottir U, Evangelou E, et al. Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet. 2012;44(5):491–501.CrossRef
40.
Massart F, Brandi ML. Genetics of the bone response to bisphosphonate treatments. Clin Cases Miner Bone Metab. 2009;6(1):50–4.PubMedPubMedCentral
41.
Giguère Y, Dodin S, Blanchet C, Morgan K, Rousseau F. The association between heel ultrasound and hormone replacement therapy is modulated by a two-locus vitamin D and estrogen receptor genotype. J Bone Miner Res. 2000;15(6):1076–84.CrossRef
42.
Silvestri S, Thomsen AB, Gozzini A, Bagger Y, Christiansen C, Brandi ML. Estrogen receptor α and β polymorphisms: is there an association with bone mineral density, plasma lipids, and response to postmenopausal hormone therapy. Menopause. 2006;13(3):451–61.CrossRef
43.
Masi L, Ottanelli S, Berni R, Cacudi E, Giusti F, Marcucci G, Cavalli L, Fossi C, Marini F, Ciuffi S, Tanini A, Brandi ML. CYP19 and ESR1 gene polymorphisms response of the bone mineral density in post-menopausal women to hormonal replacement therapy. Clin Cases Miner Bone Metab. 2014;11(1):36–43.PubMedPubMedCentral
44.
Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple outcomes of raloxifene evaluation (MORE) investigators. JAMA. 1999;282(7):637–45.CrossRef
45.
Heilberg IP, Hernandez E, Alonzo E, Valera R, Ferreira LG, Gomes SA, Bellorin-Font E, Weisinger JR. Estrogen receptor (ER) gene polymorphism may predict the bone mineral density response to raloxifene in postmenopausal women on chronic hemodialysis. Ren Fail. 2005;27(2):155–61.CrossRef
46.
Zhang ZL, He JW, Qin YJ, Huang QR, Liu YJ, Hu YQ, Li M. Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2006;23(2):129–33.PubMed
47.
Palomba S, Numis FG, Mossetti G, Rendina D, Vuotto P, Russo T, Zullo F, Nappi C, Nunziata V. Raloxifene administration in post-menopausal women with osteoporosis: effect of different BsmI vitamin D receptor genotypes. Hum Reprod. 2003;18(1):192–8.CrossRef
48.
Mencej-Bedrač S, Zupan J, Mlakar SJ, Zavratnik A, Preželj J, Marc J. Raloxifene pharmacodynamics is influenced by genetic variants in the RANKL/RANK/OPG system and in the Wnt signaling pathway. Drug Metabol Drug Interact. 2014;29(2):111–4.CrossRef
49.
Wells G, Tugwell P, Shea B, Guyatt G, Peterson J, Zytaruk N, Robinson V, Henry D, O’Connell D. Cranney a; osteoporosis methodology group and the osteoporosis research advisory group. Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev. 2002;23(4):529–39.CrossRef
50.
Delmas PD, Davis SR, Hensen J, Adami S, van Os S, Nijland EA. Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women. Osteoporos Int. 2008;19(8):1153–60.CrossRef
51.
Herrington DM, Howard TD, Hawkins GA, Reboussin DM, Xu J, Zheng SL, Brosnihan KB, Meyers DA, Bleecker ER. Estrogen receptor polymorphisms and effects of estrogen replacement on HDL cholesterol in women with coronary disease. N Engl J Med. 2002;346(13):967–74.CrossRef
52.
Lau KM, LaSpina M, Long J, Ho SM. Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. Cancer Res. 2000;60(12):3175–82.PubMed
Metadata
Title
The estrogen receptor 1 gene affects bone mineral density and osteoporosis treatment efficiency in Slovak postmenopausal women
Authors
Vladimira Mondockova
Maria Adamkovicova
Martina Lukacova
Birgit Grosskopf
Ramona Babosova
Drahomir Galbavy
Monika Martiniakova
Radoslav Omelka
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Medical Genetics / Issue 1/2018
Electronic ISSN: 1471-2350
DOI
https://doi.org/10.1186/s12881-018-0684-8

Other articles of this Issue 1/2018

BMC Medical Genetics 1/2018 Go to the issue

Research article

Birt-Hogg-Dubé syndrome in two Chinese families with mutations in the FLCN gene

Research article

HLA class I (-A, -B, -C) and class II (-DR, -DQ) polymorphism in the Mauritanian population

Research article

Heterozygous versus homozygous phenotype caused by the same MC4R mutation: novel mutation affecting a large consanguineous kindred

Case report

Renal hypouricemia caused by novel compound heterozygous mutations in the SLC22A12 gene: a case report with literature review

Research article

Clinical utility of exome sequencing in individuals with large homozygous regions detected by chromosomal microarray analysis

Research article

An African perspective on the genetic risk of chronic kidney disease: a systematic review